The Development of Cold-type Autoimmune Hemolytic Anemia during Peginterferon alfa-2a plus Ribavirin Treatment in Chronic Hepatitis C Patient: a Case Report
نویسنده
چکیده
Peginterferon-alfa 2a or alfa 2b plus ribavirin is the treatment of choice in chronic hepatitis C. Severe adverse effects may compromise efficacy of this regiment. There are few reports of warm autoimmune hemolytic anemia following interferon-alfa or peginterferon-alfa2b plus ribavirin treatment. This present report discusses autoimmune hemolytic anemia which developed during peginterferon alfa-2a/ribavirin treatment and caused dose cessation. The anemia was improved with discontinuation of peginterferon-alfa 2a/ribavirin and adminstration of erythropoietin stimulating agent. *Corresponding author: Dr. Putut Bayupurnama, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, Gadjah Mada University/Dr. Sardjito General Hospital, Yogyakarta, Indonesia, E-mail: [email protected] Received June 28, 2012; Accepted July 17, 2012; Published July 19, 2012 Citation: Bayupurnama P, Taroeno-Hariadi KW (2012) The Development of Coldtype Autoimmune Hemolytic Anemia during Peginterferon alfa-2a plus Ribavirin Treatment in Chronic Hepatitis C Patient: a Case Report. J Clin Case Rep 2:173. doi:10.4172/2165-7920.1000173 Copyright: © 2012 Bayupurnama P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Introduction Chronic hepatitis C is still a serious health problem, with limited choice of treatment. Peg interferon based treatment combined with ribavirin is the treatment of choice. The length of treatment and their responses are well predicted by their genotype. Genotype 2 and 3 have better response rate (70%) with shorter duration of combination treatment (24 weeks), while genotype 1 and 4 have poor response rate (about 45%) and need a longer treatment duration (48 weeks). The non responder rate is still high in genotype 1 HCV infection [1]. The side effects of interferon and ribavirin limit their treatment efficacy in some cases and severe side effect may urge to stop the treatment. We report a chronic hepatitis C patient who developed cold-type autoimmune hemolytic anemia during peginterferon (PegIFN) alfa-2a/ribavirin combination treatment.
منابع مشابه
Severe autoimmune hemolytic anemia during pegylated interferon plus ribavirin treatment for chronic hepatitis C: a case report
We report a rare case of severe autoimmune hemolytic anemia triggered by pegylated interferon during combination therapy for chronic HCV. This case demonstrated that interferon can de novo induce autoimmune hemolytic anemia during therapy for chronic hepatitis C in a previously healthy patient.
متن کاملSevere autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin.
Peginterferon (Peg-IFN) alfa in combination with ribavirin represents the gold standard treatment for chronic hepatitis C, but is associated with various side effects, especially hematological abnormalities. We report here a case of severe autoimmune hemolytic anemia (AIHA) complicated by symptomatic myocardial ischemia in a patient with chronic hepatitis C during combination therapy. The worse...
متن کاملPegylated interferon de novo-induce autoimmune haemolytic anaemia in chronic hepatitis C patient.
A 55-year-old Egyptian woman with chronic hepatitis C undergoing treatment with pegylated interferon (Peg-IFN) alfa-2a plus ribavirin was referred to our hospital on November 2010 with prolonged easy fatigability and an attack of syncope; she had no prior history of autoimmune disorders or allergy. Laboratory investigations documented the presence of Peg-IFN induced autoimmune haemolytic anaemi...
متن کاملAutoimmune hemolytic anemia in HCV/HIV coinfected patients during treatment with pegylated alpha-2a interferon plus ribavirin.
Two cases of autoimmune hemolytic anemia that occurred during the treatment of chronic hepatitis C with pegylated alpha-2a interferon and ribavirin, in HIV coinfected patients, are presented and described. The late occurrence (after six months of therapy) of this severe hemolytic anemia leads to the recommendation that hemoglobin levels should be monitored throughout the treatment period, even ...
متن کاملSevere muscle weakness during treatment with pegylated interferon alfa for chronic hepatitis C virus infection A rare complication
Background: Interferons (IFNs) are common therapeutics for several diseases such as viral hepatitis, multiple sclerosis and malignancy. A variety of autoimmune related side effects have been observed during IFN therapy. Rare cases of myopathy, polymyositis or dermatomyositis have been reported during therapy with high doses of IFN^5. Case Presentation: In this report, we describe a case with se...
متن کامل